Abstract | OBJECTIVE: METHODS: Multicenter, randomized, clinical trial of 271 participants. MAIN OUTCOME MEASURE: Gain in visual acuity letter score of 15 or more from baseline to month 12. RESULTS: Seven percent, 27%, and 26% of participants achieved the primary outcome in the observation, 1-mg, and 4-mg groups, respectively. The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P = .001) and 5.0 times greater in 4-mg group than the observation group (OR, 5.0; 95% CI, 1.8-14.4; P = .001); there was no difference identified between the 1-mg and 4-mg groups (OR, 1.0; 95% CI, 0.5-2.1; P = .97). The rates of elevated intraocular pressure and cataract were similar for the observation and 1-mg groups, but higher in the 4-mg group. CONCLUSIONS: Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial. The 1-mg dose has a safety profile superior to that of the 4-mg dose. Application to Clinical Practice Intravitreal triamcinolone in a 1-mg dose, following the retreatment criteria applied in the SCORE Study, should be considered for up to 1 year, and possibly 2 years, for patients with characteristics similar to those in the SCORE-CRVO trial. Trial Registration clinicaltrials.gov Identifier: NCT00105027.
|
Authors | Michael S Ip, Ingrid U Scott, Paul C VanVeldhuisen, Neal L Oden, Barbara A Blodi, Marian Fisher, Lawrence J Singerman, Michael Tolentino, Clement K Chan, Victor H Gonzalez, SCORE Study Research Group |
Journal | Archives of ophthalmology (Chicago, Ill. : 1960)
(Arch Ophthalmol)
Vol. 127
Issue 9
Pg. 1101-14
(Sep 2009)
ISSN: 1538-3601 [Electronic] United States |
PMID | 19752419
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glucocorticoids
- Triamcinolone Acetonide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Glucocorticoids
(administration & dosage, adverse effects)
- Humans
- Injections
- Macular Edema
(diagnosis, drug therapy, etiology)
- Male
- Middle Aged
- Observation
- Prospective Studies
- Retinal Vein Occlusion
(complications, diagnosis, drug therapy)
- Retreatment
- Tomography, Optical Coherence
- Treatment Outcome
- Triamcinolone Acetonide
(administration & dosage, adverse effects)
- Vision Disorders
(diagnosis, drug therapy, etiology)
- Visual Acuity
(drug effects)
- Vitreous Body
|